-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On March 23, Fuan Pharmaceutical announced that the concentrated solution of sodium valproate for injection, a wholly-owned subsidiary of Qingyutang, was approved for marketing, which is deemed to have passed the consistency evaluation
.
This variety is a commonly used anti-epileptic drug in clinical practice and is mainly suitable for the treatment of epilepsy.
In adults and children, when the oral dosage form cannot be taken temporarily, it is used to replace the oral dosage form
.
Epilepsy is a common chronic neurological disease that occurs in people of any age, region and ethnicity, among which children and the elderly are typical.
In China, the number of epilepsy patients has exceeded 9 million
.
At present, the treatment methods of epilepsy mainly include drugs, surgery and other treatments (such as diet, biofeedback, etc.
), of which about 70% of patients can get effective control of the disease through drug treatment
.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit γ-aminobutyric acid transaminase and increase the concentration of γ-aminobutyric acid to achieve anticonvulsant effect.
It is effective for localized grand mal, grand mal and mixed epilepsy, and it is mostly used for various epilepsy that other antiepileptic drugs are ineffective
.
The marketed dosage forms of the product include injections, sustained-release tablets, ordinary tablets and solutions
.
According to data from Minet.
com, in 2019, the terminal sales of sodium valproate in China's public medical institutions exceeded 2 billion yuan, and injections accounted for more than 60% of the market share
.
In recent years, with the gradual increase in the number of patients, the market size of anti-epileptic drugs has also continued to expand.
At present, the market size of terminal chemical drugs and anti-epileptic drugs in China's public medical institutions is close to 5 billion yuan
.
The market size of sodium valproate injection is also very considerable
.
According to data from Minet.
com, in 2020, the sales of terminal sodium valproate injection in China's public medical institutions will exceed 1 billion yuan
.
In the first half of 2021, the sales of this product have exceeded 700 million yuan, an increase of 21.
74% over the same period
.
From the perspective of production enterprises, the original research Sanofi occupies the main market share, followed by domestic pharmaceutical companies such as Shenyang Xinma Pharmaceutical and Sichuan Keruid Pharmaceutical
.
In terms of consistency evaluation, domestic pharmaceutical companies that have deployed sodium valproate injections have already applied for production by Renhe Yikang, Hainan Beite, and Chengdu Yuandong Biological.
Among them, Hebei Renhe Yikang Pharmaceutical Co.
, Ltd.
and Sichuan Kerui De Pharmaceutical Co.
, Ltd.
have been approved for production under the new registration classification, which is deemed to have passed the consistency evaluation
.
In addition, there are also pharmaceutical companies such as Hainan Better Pharmaceuticals that have submitted applications for generic marketing of concentrated solution of sodium valproate for injection
.
According to public information, Fuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemicals
.
The company has a complete industrial chain layout of drug research and development, pharmaceutical intermediates, APIs, preparation production and sales.
The products involve antibiotics, anti-tumor drugs, specialty drugs and other types of drugs.
The sales business covers most provinces in China.
Have product export business
.
Up to now, 15 varieties of Fuan Pharmaceutical have passed/deemed to pass the consistency evaluation
.
And 14 of the 15 over-rated varieties are injections
.
The company's performance report for the first three quarters of 2021 shows that from January 1, 2021 to September 30, 2021, the company achieved an operating income of 1.
826 billion yuan, a year-on-year increase of 0.
31%, and a net profit of 178 million yuan, a year-on-year decrease of 8.
73%.
The stock income is 0.
15 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
This variety is a commonly used anti-epileptic drug in clinical practice and is mainly suitable for the treatment of epilepsy.
In adults and children, when the oral dosage form cannot be taken temporarily, it is used to replace the oral dosage form
.
Epilepsy is a common chronic neurological disease that occurs in people of any age, region and ethnicity, among which children and the elderly are typical.
In China, the number of epilepsy patients has exceeded 9 million
.
At present, the treatment methods of epilepsy mainly include drugs, surgery and other treatments (such as diet, biofeedback, etc.
), of which about 70% of patients can get effective control of the disease through drug treatment
.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug, which can competitively inhibit γ-aminobutyric acid transaminase and increase the concentration of γ-aminobutyric acid to achieve anticonvulsant effect.
It is effective for localized grand mal, grand mal and mixed epilepsy, and it is mostly used for various epilepsy that other antiepileptic drugs are ineffective
.
The marketed dosage forms of the product include injections, sustained-release tablets, ordinary tablets and solutions
.
According to data from Minet.
com, in 2019, the terminal sales of sodium valproate in China's public medical institutions exceeded 2 billion yuan, and injections accounted for more than 60% of the market share
.
In recent years, with the gradual increase in the number of patients, the market size of anti-epileptic drugs has also continued to expand.
At present, the market size of terminal chemical drugs and anti-epileptic drugs in China's public medical institutions is close to 5 billion yuan
.
The market size of sodium valproate injection is also very considerable
.
According to data from Minet.
com, in 2020, the sales of terminal sodium valproate injection in China's public medical institutions will exceed 1 billion yuan
.
In the first half of 2021, the sales of this product have exceeded 700 million yuan, an increase of 21.
74% over the same period
.
From the perspective of production enterprises, the original research Sanofi occupies the main market share, followed by domestic pharmaceutical companies such as Shenyang Xinma Pharmaceutical and Sichuan Keruid Pharmaceutical
.
In terms of consistency evaluation, domestic pharmaceutical companies that have deployed sodium valproate injections have already applied for production by Renhe Yikang, Hainan Beite, and Chengdu Yuandong Biological.
Among them, Hebei Renhe Yikang Pharmaceutical Co.
, Ltd.
and Sichuan Kerui De Pharmaceutical Co.
, Ltd.
have been approved for production under the new registration classification, which is deemed to have passed the consistency evaluation
.
In addition, there are also pharmaceutical companies such as Hainan Better Pharmaceuticals that have submitted applications for generic marketing of concentrated solution of sodium valproate for injection
.
According to public information, Fuan Pharmaceutical is mainly engaged in the research and development, production and sales of chemicals
.
The company has a complete industrial chain layout of drug research and development, pharmaceutical intermediates, APIs, preparation production and sales.
The products involve antibiotics, anti-tumor drugs, specialty drugs and other types of drugs.
The sales business covers most provinces in China.
Have product export business
.
Up to now, 15 varieties of Fuan Pharmaceutical have passed/deemed to pass the consistency evaluation
.
And 14 of the 15 over-rated varieties are injections
.
The company's performance report for the first three quarters of 2021 shows that from January 1, 2021 to September 30, 2021, the company achieved an operating income of 1.
826 billion yuan, a year-on-year increase of 0.
31%, and a net profit of 178 million yuan, a year-on-year decrease of 8.
73%.
The stock income is 0.
15 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
